Promising Results for Candel Therapeutics' Non-Metastatic Pancreatic Cancer Treatment
Thursday, 4 April 2024, 12:36
Promising Interim Data for CAN-2409
Candel Therapeutics has announced positive results for its non-metastatic pancreatic cancer treatment, CAN-2409. The interim data from a mid-stage trial indicates improved overall survival rates at 24 and 36 months.
Impact on Pancreatic Cancer Treatment
- Improved Survival Rates: Results show promising outcomes for patients with non-metastatic pancreatic cancer.
- Potential Treatment Efficacy: CAN-2409 demonstrates potential as an effective treatment option.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.